2018
DOI: 10.1016/j.kint.2017.05.013
|View full text |Cite
|
Sign up to set email alerts
|

Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism

Abstract: Inflammation plays a central role in the etiology of diabetic nephropathy, a global health issue. We observed a significant reduction in the renal expression of fibroblast growth factor 1, a known mitogen and insulin sensitizer, in patients with diabetic nephropathy and in mouse models implying that fibroblast growth factor 1 possesses beneficial anti-inflammatory and renoprotective activities in vivo. To test this possibility, we investigated the effects of chronic intraperitoneal administration of fibroblast… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

15
105
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
7

Relationship

3
4

Authors

Journals

citations
Cited by 124 publications
(120 citation statements)
references
References 45 publications
15
105
0
Order By: Relevance
“…Specific treatment of patients with diabetic nephropathy can be divided into 4 major arenas: cardiovascular risk reduction, glycemic control, blood pressure control, and inhibition of the renin‐angiotensin system (RAS) . Our previous studies have demonstrated that FGF1 administration protected against renal injury by reducing inflammation . Based on previous study, our current study had further confirmed that FGF1 administration ameliorated diabetes‐induced glomerular damage and interstitial fibrosis.…”
Section: Discussionsupporting
confidence: 64%
See 2 more Smart Citations
“…Specific treatment of patients with diabetic nephropathy can be divided into 4 major arenas: cardiovascular risk reduction, glycemic control, blood pressure control, and inhibition of the renin‐angiotensin system (RAS) . Our previous studies have demonstrated that FGF1 administration protected against renal injury by reducing inflammation . Based on previous study, our current study had further confirmed that FGF1 administration ameliorated diabetes‐induced glomerular damage and interstitial fibrosis.…”
Section: Discussionsupporting
confidence: 64%
“…Fibroblast growth factor 1 (FGF1) is an autocrine/paracrine regulator and known to act on cells from a variety of tissue origins including the liver, vasculature, and skin, exerting classic mitogenic activity and neuroprotective role . Our previous study had demonstrated that FGF1 treatment ameliorated diabetes‐induced nephropathy by inhibiting inflammation via JNK/NF‐kB signalling pathway . But there are no studies to focus on the effect of FGF1 on cellular stress during FGF1 treatment for DN.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…JNK and NF‐κB signalling pathways are involved in the expression of α‐SMA and collagen 7, 8. Protein levels of p‐JNK and NF‐κB were increased in LX‐2 cells activated by TGF‐β1, and this increase was inhibited by FGF21_ADSCs CM treatment but not by Empty_ADSCs CM or 200 pg/mL FGF21 (Figure 2C,D).…”
Section: Resultsmentioning
confidence: 95%
“…In the year 2018, several compounds like berberine, gallic acid, ligustrazine, nifuroxazide, pentoxifylline, rosuvastatin, and so forth to treat kidney damage in type 1 diabetes and compounds like dihydroquercetin, cinacalcet, cyanidin‐3‐O‐glucoside, zingerone, glucagon‐like peptide‐1 (GLP‐1) co‐agonist, dapagliflozin, pioglitazone, and fibroblast growth factor 1 to treat kidney damage in type 2 diabetes have been studied so far. Compound like carnosic acid was found to ameliorate kidney damage in both type 1 and type 2 diabetes (Ding et al, ; Elhawary, Ibrahim, & Attallah, ; Elsherbiny, Zaitone, Mohammad, & El‐Sherbiny, ; Garud & Kulkarni, ; Han et al, ; Liang et al, ; Lim et al, ; Patel et al, ; Qin et al, ; Rehman et al, ; Xie et al, ; Yang & Wu, ; Zhu, Han, Yuan, Xue, & Pang, ).…”
Section: Introductionmentioning
confidence: 99%